Arrowhead Pharmaceuticals (ARWR) Return on Invested Capital (2025 - 2026)

Arrowhead Pharmaceuticals (ARWR) posted Return on Invested Capital of 0.01% for Q1 2026, down 183.49% on a QoQ basis from 0.02% in Q4 2025, and up 2.0% year-over-year from 0.01% in Q1 2025.

Arrowhead Pharmaceuticals (ARWR) Return on Invested Capital (2025 - 2026) Analysis & Trends

Arrowhead Pharmaceuticals' Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.01% for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.00%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.04%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arrowhead Pharmaceuticals 11.98 Bn 10.18 Bn - -0.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.01%
Dec 31, 2025 0.02%
Sep 30, 2025 0.00%
Jun 30, 2025 -0.01%
Mar 31, 2025 -0.04%